Moderna Inc (NASDAQ:MRNA)’s traded shares stood at 9.3 million during the last session, with the company’s beta value hitting 1.84. At the close of trading, the stock’s price was $34.98, to imply an increase of 2.37% or $0.81 in intraday trading. The MRNA share’s 52-week high remains $170.47, putting it -387.34% down since that peak but still an impressive 8.69% since price per share fell to its 52-week low of $31.94. The company has a valuation of $13.46B, with an average of 14.29 million shares in intraday trading volume over the past 10 days and average of 10.78 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Moderna Inc (MRNA), translating to a mean rating of 2.79. Of 17 analyst(s) looking at the stock, 2 analyst(s) give MRNA a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 12 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -2.72.
Moderna Inc (NASDAQ:MRNA) trade information
After registering a 2.37% upside in the last session, Moderna Inc (MRNA) has traded red over the past five days. The 5-day price performance for the stock is -14.10%, and -17.07% over 30 days. With these gigs, the year-to-date price performance is -15.87%. Short interest in Moderna Inc (NASDAQ:MRNA) saw shorts transact 43.01 million shares and set a 4.04 days time to cover.
The extremes give us $55 and $238 for target low and target high price respectively. As such, MRNA has been trading -580.39% off suggested target high and -57.23% from its likely low.
Moderna Inc (MRNA) estimates and forecasts
Looking at statistics comparing Moderna Inc share performance against respective industry, we note that the company has outperformed competitors. Moderna Inc (MRNA) shares are -58.23% down over the last 6 months, with its year-to-date growth rate higher than industry average at 25.55% against 16.00%. The rating firms project that company’s revenue will shrink -52.92% compared to the previous financial year.
Revenue forecast for the current quarter as set by 16 analysts is 951.09M. Meanwhile, for the current quarter, a total of 7 analyst(s) estimate revenue growth to 190.36M.Earnings reports from the last fiscal year show that sales brought in 2.81B and 167M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -66.17% before jumping 13.99% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -20.02% for the past 5-year period. While 2025 is set for a 26.77% return in earnings, projections for the next 5 years are at 16.93% annually.
MRNA Dividends
Moderna Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Moderna Inc (NASDAQ:MRNA)’s Major holders
Moderna Inc insiders hold 9.52% of total outstanding shares, with institutional holders owning 68.09% of the shares at 75.26% float percentage. In total, 68.09% institutions holds shares in the company, led by BAILLIE GIFFORD & CO. As of 2024-06-30, the company held over 43.45 million shares (or 11.3741% of shares), all amounting to roughly $5.16 billion.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 39.56 million shares, or about 10.3568% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $4.7 billion.
We also have Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund as the top two Mutual Funds with the largest holdings of the Moderna Inc (MRNA) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 11.0 shares. This is just over 2.86% of the total shares, with a market valuation of $384.7 million. Data from the same date shows that the other fund manager holds a little less at 8.86, or 2.30% of the shares, all valued at about 309.87 million.
